🔗 Share this article

Given that America proceeds with historic adjustments to its vaccination guidelines, an unexpected name has surfaced unexpectedly: Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by casting doubt on COVID-19 vaccines throughout the pandemic and has focused upon possible deaths following COVID-19 vaccination in her short tenure at the FDA.

Scheduled Overhauls to Pediatric Vaccine Program

Public health authorities were set to announce radical revisions to the childhood vaccination calendar recently, bringing the US with the Danish immunization schedule, it is understood – a substantial departure that would place the US at odds with many the global community with no evidence for improved outcomes. The planned update has been postponed until the new year.

Rather than the top vaccines chief, Dr. Høeg is listed to address the audience at the meeting. She was recently named temporary leader of the FDA’s CDER, the fifth appointee to run the office this year.

A New Direction at the Agency

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad consolidate power at the FDA – and it suggests a greater focus upon rolling back already-approved immunizations at the FDA.

Høeg has repeatedly called for ending certain childhood vaccine recommendations in the US to become more similar to the Danish model, a nation with comprehensive healthcare and a number of inhabitants roughly the size of Wisconsin’s.

So far statements, she has kept her attention on vaccination policy – usually the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – rather than drug regulation.

Concerns Over Expertise

Høeg has little discernible experience in drug development, approval processes or administrative roles, which has been typical for former directors of the CBER. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since spring.

“She appears not to have any of the qualifications” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a large organization. She is not an expert in industry regulation.”

Former heads of CBER would “be deeply familiar with laws and regulations and the research of drug development”, said Dr. Janet Woodcock. “Objectively, she lacks the kind of background that former directors who ran CBER have had.”

This division has an vast portfolio at the FDA, she stated.

“Everybody just focuses on the new drug program, but the off-patent medication office clears a multitude of generic medications. There is also a biosimilars division, non-prescription drug unit and other areas, and every single one have to be looked after,” she noted. “The area you neglect, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial leadership element to the job, which oversees more than 5,000 employees. “It is a massive administrative position, if you do it right,” Woodcock said.

Response and Controversial Policies

Regarding concerns about Høeg’s credentials and whether this assignment signifies increased cooperation among agency officials on immunizations, a representative said that the “questions are based on flawed assumptions”.

“This background is consistent with the functions of her role,” the representative explained, pointing to the months Høeg spent advising the agency head on “drug safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg inherits the commissioner’s new priority voucher program, a disputed expedited medication authorization process that allegedly worried her preceding directors. “How are these therapies being chosen for this fast-track system? Who takes the decisions?” Dr. Howard questioned. “There is a lot of lack of transparency occurring at the agency right now.”

Broadly speaking, he stated, “the FDA appears to be shifting towards less stringent rules of most medications, aside from vaccines.”

Public Past Work on Immunizations

Regarding vaccines, Høeg has a clearer, if concerning, history, critics said. She released a study using unconfirmed public submissions to estimate the frequency of myocarditis after COVID-19 vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who was said to have changed statistics to indicate Covid vaccinations are more dangerous than they are.

Included in her “wish list” for the incoming administration encompassed changing rules for recently developed shots and discontinuing “unnecessary” immunizations, she said post-election on a online show. At the FDA, Dr. Høeg has according to sources proposed excluding teenage boys from obtaining COVID-19 vaccinations.

“She is an thorough true believer who begins with her beliefs and works backwards to retrofit the data in a very deceptive, untruthful way,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Dr. Høeg became part of fellow skeptics, {like|